Background: Stroke registries provide a simple way for improving patient care, and its use has been associated with a better adherence to the published guidelines. Few Latin American countries had established stroke registries. Our study is the first in Mexico to report the effects of implementing a stroke registry. To determine if the implementation of a systematized registry is associated with an improved adherence to the performance measures.
Methods: We compared prospective data (August 2008-November 2010) against historical controls (February 2005-July 2008). Our stroke registry (i-Registro Neurovascular) consists of a standardized clinical form that includes demographic and clinical variables (risk factors, medications, neuroimaging, etiology, acute and outpatient treatments, and neurologic scores [National Institutes of Health Stroke Scale and modified Rankin Scale]). We evaluated 9 performance measures suggested by the American Heart Association and the Joint Commission.
Results: We analyzed the data from 574 patients, 260 from the prospective phase and 314 from historical controls. No significant statistical differences in demographic characteristics or stroke risk factors were found. The implementation of the stroke registry was associated with a statistically significant (P < .05) improvement in almost all of the acute performance measures. The composite measure also showed an improvement form 52.6%-68.8% (P < .001).
Conclusions: The implementation of a systematized registry significantly improved our clinical practice. This intervention is a low cost and readily achievable and a viable option for encouraging an increased report of guidelines adherence of other hospitals in Latin America.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review of current national hospital-based stroke registries monitoring access to evidence-based care and patient outcomes.
Eur Stroke J
January 2025
Stroke and Elderly Care Medicine, University of Edinburgh, Edinburgh, UK.
Background: National stroke clinical quality registries/audits support improvements in stroke care. In a 2016 systematic review, 28 registries were identified. Since 2016 there have been important advances in stroke care, including the development of thrombectomy services.
View Article and Find Full Text PDFPrognostic Value of Ambulatory Status at Transplant in Older Heart Transplant Recipients: Implications for Organ Allocation Policy.
J Korean Med Sci
January 2025
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Background: Shortage of organ donors in the Republic of Korea has become a major problem. To address this, it has been questioned whether heart transplant (HTx) allocation should be modified to reduce priority of older patients. We aimed to evaluate post-HTx outcomes according to recipient age and specific pre-HTx conditions using a nationwide prospective cohort.
View Article and Find Full Text PDFBackground: Growth differentiation factor 15 (GDF15) is a cytokine responding to oxidative stress and inflammation, and it regulates appetite and energy balance. The association between GDF15 and clinical factors and its prognostic value in elderly multimorbid patients with heart failure with preserved ejection fraction (HFpEF) have not been well unknown.
Methods: This exploratory analysis is part of the Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with preserved Ejection Fraction study (N=1231), an ongoing, prospective, multicentre observational study of acute decompensated HFpEF (UMIN000021831).
Aims: This study aimed to determine the robustness, reproducibility and representativeness of the landmark Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (AF) (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF (ROCKET AF) randomised trials through replication in an observational AF patient registry.
Methods And Results: Patients from the Global Anticoagulant Registry in the FIELD (GARFIELD)-AF registry treated with apixaban, rivaroxaban or vitamin K antagonist (VKA) were assessed for eligibility for the ARISTOTLE and ROCKET AF trials. HRs of apixaban and rivaroxaban versus comparator for stroke/systemic embolism, major bleeding and all-cause mortality within 2 years follow-up were calculated using propensity score overlap-weighted Cox models.
[Clinical and epidemiological indicators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region].
Zh Nevrol Psikhiatr Im S S Korsakova
January 2025
Vladimirskii Moscow Regional Research and Clinical Institute, Moscow, Russia.
Objective: To analyze the dynamics of clinical and epidemiological indicators of stroke and the features of providing specialized care to patients in the Moscow region in the period 2019-2023.
Material And Methods: Mortality rates, the average annual population, and the number of deaths in one-year age groups were analyzed based on the «Brief Nomenclature of Causes of Death» by ROSSTAT and the database of the Registry Office of the Moscow Region. Depersonalized data on deceased individuals aged 18 years and older were obtained from this database, including codes and names of diseases or conditions specified in Parts I and II of the medical death certificate, age, sex, and place of death for the period 2019-2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!